Nord/LB set a €72.00 ($83.72) price target on Bayer (FRA:BAYN) in a research report report published on Tuesday. The brokerage currently has a neutral rating on the healthcare company’s stock.

A number of other equities research analysts also recently issued reports on BAYN. Independent Research set a €85.00 ($98.84) price objective on shares of Bayer and gave the stock a neutral rating in a research report on Wednesday, September 5th. Kepler Capital Markets set a €84.00 ($97.67) price objective on shares of Bayer and gave the stock a buy rating in a research report on Monday. Barclays set a €100.00 ($116.28) price objective on shares of Bayer and gave the stock a buy rating in a research report on Tuesday. Jefferies Financial Group set a €77.00 ($89.53) price objective on shares of Bayer and gave the stock a neutral rating in a research report on Tuesday. Finally, Deutsche Bank set a €127.00 ($147.67) price objective on shares of Bayer and gave the stock a buy rating in a research report on Friday, November 2nd. Seven research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of €94.12 ($109.44).

FRA:BAYN opened at €62.94 ($73.19) on Tuesday. Bayer has a one year low of €91.58 ($106.49) and a one year high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Recommended Story: What factors cause inflation to rise?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.